Inhibitory effects of incadronate on the progression of rat experimental periodontitis by porphyromonas gingivalis infection.
BACKGROUND
Incadronate (YM175, disodium cycloheptylaminomethylenediphosphonate monohydrate), a bisphosphonate, has been suggested to prevent the bone resorption associated with periodontitis by inhibiting osteoclast activity. The purpose of this study was to investigate the effect of incadronate in preventing periodontal destruction in rats with Porphyromonas gingivalis-induced periodontitis.


METHODS
Periodontitis was induced in 35 Wister rats by inoculating P. gingivalis into the oral cavity and feeding the rats a soft diet for 4 weeks. Incadronate or placebo was administered to the oral cavity of the rats 2 days per week for 2, 4, or 8 weeks.


RESULTS
P. gingivalis infection resulted in destruction of the periodontal ligament, reduced bone density, and caused inflammatory cell migration. Radiographic, morphometric, and histological results showed that incadronate had the ability to increase the bone mineral density (quantum level score; cortex 518.9 [placebo 612.8]; sponge 579.8 [placebo 672.0]) and to prevent periodontal ligament destruction (width 0.16 mm [placebo 0.20 mm]; area 0.36 mm2 [placebo 0.54 mm2]) after 8 weeks' administration. Furthermore, the polymorphonuclear leukocyte (PMN) infiltration in gingival tissue was significantly decreased.


CONCLUSIONS
These results showed that incadronate inhibits bone resorption and PMN migration in P. gingivalis-induced periodontitis.
Tani-Ishii
Nobuyuki
N
Department of Operative Dentistry and Endodontics, Kanagawa Dental College,Yokosuka, Kanagawa, Japan. nobu0337@kdcnet.ac.jp
Minamida
Genshi
G
Saitoh
Daisuke
D
Chieda
Keiko
K
Omuro
Hiromasa
H
Sugaya
Akira
A
Hamada
Nobushiro
N
Takahashi
Yusuke
Y
Kiyohara
Shiro
S
Kashima
Isamu
I
Teranaka
Toshio
T
Umemotot
Toshio
T
D016301:Alveolar Bone Loss / Q000503:physiopathology / Q000517:prevention & control; D000704:Analysis of Variance; D000818:Animals; D016866:Bacteroidaceae Infections / Q000503:physiopathology / Q000517:prevention & control*; D015519:Bone Density / Q000187:drug effects / Q000502:physiology; D002465:Cell Movement / Q000187:drug effects; D004164:Diphosphonates / Q000627:therapeutic use*; D004195:Disease Models, Animal; D018450:Disease Progression; D005260:Female; D009504:Neutrophils / Q000187:drug effects / Q000502:physiology; D010513:Periodontal Ligament / Q000187:drug effects / Q000382:microbiology; D010518:Periodontitis / Q000382:microbiology / Q000517:prevention & control*; D010919:Placebos; D016966:Porphyromonas gingivalis / Q000187:drug effects*; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors
D004164:Diphosphonates; D010919:Placebos; C071542:cimadronate